10-Q: BriaCell Therapeutics Reports Significant Cash Inflow and Promising Clinical Trial Progress Amidst Expanding Losses

BriaCell Therapeutics Corp. reported a substantial increase in cash and a swing to positive working capital driven by multiple equity offerings, while continuing to advance its Bria-IMT and Bria-OTS immunotherapy programs for metastatic breast cancer despite widening net losses.

Summary

• BriaCell Therapeutics Corp. ended the period with $12,460,253 in cash and cash equivalents as of April 30, 2025, a significant increase from $862,089 on July 31, 2024.
• The company's total current assets rose to $14,785,198 as of April 30, 2025, up from $3,653,854 on July 31, 2024.
• Shareholders' equity swung to a positive balance of $11,941,153 as of April 30, 2025, compared to a deficit of $(2,684,932) on July 31, 2024.
• The net loss for the nine months ended April 30, 2025, significantly increased to $(18,392,033) from $(3,682,796) for the same period in 2024, primarily due to a smaller non-cash gain from the change in fair value of warrant liability.
• Research, development, and clinical trial expenses decreased to $14,160,314 for the nine months ended April 30, 2025, from $22,772,344 in the prior year, mainly due to the conclusion of the Bria-IMT Phase 1/2a trial.
• The Bria-IMT pivotal Phase 3 study has consented over 100 and enrolled over 75 patients, with enrollment anticipated to complete in late 2025 or early 2026, and top-line data expected as early as H1-2026.
• Bria-OTS, a personalized immunotherapy, showed a complete resolution of lung metastasis in the first metastatic breast cancer patient treated, with the patient remaining on study with stable disease elsewhere.
• The company successfully completed multiple public offerings, raising aggregate gross proceeds of approximately $35.9 million between September 2024 and April 2025.
• A 1-for-15 reverse stock split was implemented on January 24, 2025, to maintain Nasdaq listing compliance.
• BriaPro Therapeutics Corp., a 2/3rd owned subsidiary, is developing novel high-affinity antibodies to B7-H3 and has filed provisional US patent applications for the technology.

Sentiment

Score: 6

Explanation: The company shows strong clinical progress and has successfully raised significant capital, improving its liquidity and balance sheet. However, the substantial increase in net loss and the explicit 'going concern' uncertainty temper the overall positive sentiment, indicating high operational burn and continued reliance on external funding.

Positives

• Significant increase in cash and cash equivalents to $12.46 million, providing enhanced liquidity.
• Successful capital raises totaling approximately $35.9 million gross proceeds from September 2024 to April 2025, demonstrating strong investor confidence and funding capacity.
• Swing to positive shareholders' equity of $11.94 million from a deficit of $(2.68) million, indicating improved financial stability.
• Positive clinical response observed with Bria-OTS, including 100% resolution of lung metastasis in a metastatic breast cancer patient, supporting the personalized immunotherapy approach.
• Bria-IMT plus CPI showed superior median overall survival (17.3 months) in HR+ metastatic breast cancer patients compared to TRODELVY (14.4 months), a current standard of care.
• Phase 3 clinical study of Bria-IMT is progressing with over 75 patients enrolled and over 100 consented, indicating steady trial advancement.
• Identification of potential predictive biomarkers (DTH, NLR, CTC) in Phase 3 data, which could improve patient outcomes and treatment stratification.
• Bria-IMT Phase 3 regimen demonstrated a positive tolerability profile.
• Bria-OTS Phase 1/2 study cleared safety evaluation and has transitioned to combination dosing with immune checkpoint inhibitors, expanding its clinical development.
• BriaPro Therapeutics Corp. is actively developing novel anti-B7-H3 antibodies and has filed patent applications, indicating pipeline expansion and innovation.

Negatives

• Net loss for the nine months ended April 30, 2025, significantly widened to $(18,392,033) from $(3,682,796) in the prior year, primarily due to a reduced non-cash gain from warrant liability fair value changes.
• Accumulated deficit increased to $(103,664,194) as of April 30, 2025, reflecting ongoing operational losses.
• The company continues to sustain operating losses and expects them to continue in the foreseeable future, highlighting the long-term financial challenge.
• High cash burn from operating activities, with $20,038,075 used in the nine months ended April 30, 2025.
• The company's ability to continue as a going concern is dependent on its ability to raise additional financing, which is not assured.

Risks

• The Company's ability to continue as a going concern is dependent upon its ability to attain future profitable operations and to obtain the necessary financing to meet its obligations, which casts substantial doubt on its ability to continue.
• There is no assurance that the Company will be able to raise sufficient additional capital through debt or equity financings to fund its operations and achieve its business plan objectives.
• If the Company is unsuccessful in obtaining additional capital, it may need to curtail or cease its operations and implement a plan to extend payables or reduce overhead.
• The Company is exposed to financial risk arising from fluctuations in foreign exchange rates, particularly with Canadian Dollar transactions.
• The fair value of warrant liabilities is subject to market fluctuations and valuation model assumptions, which can lead to significant non-cash gains or losses.

Future Outlook

BriaCell anticipates completing patient enrollment for its pivotal Phase 3 Bria-IMT study in late 2025 or early 2026, with top-line data potentially available as early as H1-2026. The company plans to continue financing its operations by exploring additional sources of capital and managing existing working capital resources, acknowledging its dependence on future financing to continue as a going concern.

Management Comments

• "The decrease in research, development, and clinical trial costs reflects the conclusion of the Bria-IMT Phase 1/2a trial and a focus on optimizing expenditures for the pivotal Phase 3 trial."
• "Current spending for the pivotal Phase 3 study is concentrated on ongoing patient recruitment, treatment, and data-management costs as we push toward key milestones."
• "We remain committed to advancing the pivotal Phase 3 study of Bria-IMT in advanced breast cancer and continue to allocate resources strategically to ensure its successful execution."
• "Management believes that it can be successful in obtaining additional capital; however, there can be no assurance that the Company will be able to do so."
• "We continue to reduce expenditure on certain non-core activities whilst maintaining our focus on our Phase 3 Bria-IMT pivotal study in advanced metastatic breast cancer."

Industry Context

BriaCell operates in the highly competitive and capital-intensive clinical-stage biotechnology sector, specifically focusing on cancer immunotherapies. The company's Bria-IMT and Bria-OTS programs are positioned within the growing field of personalized and targeted cancer treatments. The positive survival data for Bria-IMT in HR+ MBC patients, outperforming a current ADC standard of care like TRODELVY, suggests a potentially competitive profile in a significant market segment. The development of B7-H3 antibodies by its subsidiary BriaPro aligns with industry trends exploring novel immune checkpoint targets. The reliance on frequent capital raises is typical for clinical-stage biotech companies with no revenue, highlighting the need for continuous funding to advance costly clinical trials.

Comparison to Industry Standards

• Bria-IMT plus CPI in HR+ metastatic breast cancer patients achieved a median overall survival (OS) of 17.3 months, which exceeds TRODELVY (sacituzumab govitecan-hziy) at 14.4 months for HR+ patients with 4 prior lines of therapy.
• In triple-negative breast cancer (TNBC), Bria-IMT plus CPI showed a median OS of 11.4 months, which is similar to TRODELVY (11.8 months for TNBC patients with 3 prior chemotherapy-containing regimens) but markedly higher (70% increase) than single-agent chemotherapy (6.9 months).
• The clinical response of 100% resolution of lung metastasis with Bria-OTS monotherapy in a metastatic breast cancer patient is a notable outcome, particularly for a personalized off-the-shelf immunotherapy in early-stage clinical development.
• The company's ability to raise approximately $35.9 million in gross proceeds through multiple offerings within a nine-month period demonstrates a strong capacity to attract capital, which is crucial for clinical-stage biotech companies that typically have high R&D expenditures and no product revenue.

Corporate Governance

Related Party Transactions

• On August 31, 2023, the Company and BriaPro Therapeutics Corp. (a 2/3rd owned subsidiary) executed a transition services agreement, where BriaCell provides research and development and head office services to BriaPro for a fixed monthly fee of $20,000.
• The Company has a 60.9% interest in BC Therapeutics, Inc. and has provided funding and exercised options to increase its ownership, with two BriaCell representatives on BC Therapeutics' four-member board. The investment is accounted for using the equity method.
• Certain directors and officers agreed to defer payment of their directors fees/compensation for several months during calendar year 2024 until a financing was completed, after which these fees were paid in full.
• Certain officers have indicated their willingness to receive a portion of their compensation in equity of the Company, subject to applicable Nasdaq rules.

Stakeholder Impact

• **Shareholders**: Experienced a 1-for-15 reverse stock split, which reduced the number of shares but increased the per-share price, aimed at maintaining Nasdaq listing. Dilution from multiple capital raises, but also potential for value appreciation if clinical trials succeed. The swing to positive equity is beneficial.
• **Employees**: Wages and salaries increased, reflecting additional hiring. Share-based compensation is a component of their remuneration.
• **Customers (Patients)**: Potential beneficiaries of novel immunotherapies (Bria-IMT, Bria-OTS) for metastatic breast cancer, with promising clinical data suggesting improved survival and treatment responses.
• **Creditors**: Improved liquidity and positive working capital reduce immediate credit risk, but the 'going concern' uncertainty remains a long-term consideration.
• **Regulatory Authorities (FDA)**: The Bria-IMT pivotal Phase 3 study has Fast Track Designation, indicating FDA's recognition of its potential to address unmet medical needs, which could accelerate review and approval.

Next Steps

• Complete patient enrollment for the Bria-IMT pivotal Phase 3 study in late 2025 or early 2026.
• Report top-line data for the Bria-IMT pivotal Phase 3 study as early as H1-2026.
• Continue to advance the Bria-OTS Phase 1/2 study, including dosing patients in combination with immune checkpoint inhibitors.
• BriaPro Therapeutics Corp. plans to file an international patent application under the Patent Cooperation Treaty (PCT) for its B7-H3 antibody technology.
• BriaPro plans to develop anti-B7-H3 antibodies for multiple cancer indications and incorporate them into its Bria-TILsRx platform.
• The company plans to explore additional sources of capital and financing to fund future operations.

Key Dates

Recommendation

Keywords

Biotechnology, Immunotherapy, Cancer Treatment, Metastatic Breast Cancer, Bria-IMT, Bria-OTS, Clinical Trials, Phase 3 Study, FDA Fast Track, Oncology, SEC Filing, 10-Q, Capital Raise, Reverse Stock Split, BriaPro Therapeutics, B7-H3 Antibodies